London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Here's Lindy, Cliff and Chippers trying for that pivotal year
https://www.youtube.com/watch?v=QcnogXICTeA
Steve,
An anagram of Pivotal Year is Lavatory Pie.
Did someone say pivotal year? again?!
Yeah, I think that is the case too and once one does watch the others come as it really seems there is a herd mentality when it comes to yet to be proved but potentially game-changing techs no one likes to take the risk but once one does no one wants to not take the risk lol... Obviously we hope they nail that TCR deal and Glycan/Avidimab deals this year ...All we know is those collaborations with that end are indeed here so it is a wait and see but the odds are better than ever before
Crumbs... you say....But when project Blueprint appeared and you saw the list of people Lindy had managed to attract to work under her leadership and you realise wow this is not as under the radar as we once thought, at least not in the Immuno oncology circles that matter.....
I know for a fact what a small world this is, we may be told about NDAs but everyone in the industry will know who is working on what ! Guess the question is ...who will blink first !
I forgot CRUK which is also a collaboration with a potential commercial outcome...
So 6 potential commercial outcomes all with many potential Cancer Targets ... Also I do not dismiss the possibility of modi 1 still gaining a partner once the final manufacturing hurdle has been jumped... Cliff tells me they are in constant talks about all techs all the time... yeah he would say that ....But when project Blueprint appeared and you saw the list of people Lindy had managed to attract to work under her leadership and you realise wow this is not as under the radar as we once thought, at least not in the Immuno oncology circles that matter.
Crumbs... Hard to argue against your last post ! Excellent factual summary of the opportunity !
DE bought a million after the Vulpes coming in news ...He holds them in the highest regards and did try in his time to get them invested....This is not VAL a BOD lifestyle vechile of disgarded techs brought in and 'pimped up' (their own words) then the whole risk of that going nowhere (as it has) offloaded onto gullible investors some of whom are amazingly still buying it!!!!! No scancell all in house totally novel techs enough PHD's on team scancell science to rival the likes of BioNTech and others the very fact modi1 is a pioneering never before produced product goes to just show how cutting edge the science is here and means the IP will not be able to be just copied and knocked out by anyone wanting to make copies of .....Different class... yet to be rewarded....but those collaborations are here if we add in TCR we have 4 collaborations all potentially ending with commercial deal/s ...Try before you buy or in TCR's case gain huge knowhow and possibly end up with a none IP dilutive validating commercial deal.
I'm guessing that the lifestyle company attitude hadn't kicked in by 2013, so Lindy and Richard has to sell 1.3% of their joint holdings to pay for the next Christmas party.
Is that the best negative he can find in almost six and a half years? I think we can agree that's really rather reassuring. That was 0.0132294381457619 of their combined holding. Not quite so long ago as to be in Pounds shillings and pence, but getting on...
Knowlesi .. £30,000 worth (each) many many years ago .. you can try and convince yourself that its relevant today ... but a sustained self off did not happen by the joint CEO Directors .
The Company has been notified that on 21 October 2013 Lindy Durrant and Richard Goodfellow each sold 100,000 shares in the Company from their respective holdings held jointly with Scancell Employee Benefit Trust at a price of 30 pence per share.
Following these transactions their holdings in the Company are as follows:
Director Name No. of shares held in own sole name post transaction No. of shares held jointly with Scancell Employee Benefit Trust post transaction
Lindy Durrant 1,606,960 8,773,960
Richard Goodfellow 200,000 6,343,840
So for the last director's Dealing' RNS we have to go back all the way to 17th December last year for a purchase of 2,925,000 shares.
What I'd really like is for my shares to bond to a few quid, covalent or ionic, don't mind really.
Rats,
Yes, DE (allegedly) did buy a million (allegedly) recently (allegedly)
yes Rats ...
Ray the FC part of the antibody is the area that locks onto other immune effector cells ...ie covalent bonding
scancell avidmab is non covalent bonding which has reinstated the Mabs ability to act alone by actively killing a cell by
“immunogenic cell death” (ICD)
it then talks to other areas of the immune system via ""damage-associated molecular pattern "" which are released by the cell that the Mab has bind to ..
this really is complex chemistry
https://www.frontiersin.org/articles/10.3389/fimmu.2017.01860/full
Didn't DE allegedly buy a million recently?
Lindy does not need to buy more shares, it is pretty simple really ..... they keep adding to the value of the IP ... just because the market cannot value Moditope or Avidmab ... does not mean the Directors cannot ...even DE accepts that an end loaded deal would still attract a premium over the current share price by a factor of 3 because we are vulnerable . Yet you still crave for your 3p buy ... when in reality you could not even pass off as a window cleaner as you keep missing the windows to buy
but what does Vulnerable mean . ?? we are to cheap
Vulpes recently took a chunk off the market and a few of us pi still buying
Yeah... All I can say is Cliff to me seemed quite confident on their being a 'transactions later this year' The fact 3 collaborators have come in rather fast shows the interest is real and not made up and like I say fact these techs have such broad application potential and that whoever these collaborators are are capable at looking at the techs in all those applications shows they must be rather capable collaborators as that is a lot of complicated lab work
I wonder how unique Avidimab is.
I imagine that Mabs attach themselves to a tumour and then join with each other via the mutual attraction of the Fc region (tail of Mab). I imagine this forms a blanket over the tumour that is harder to dislodge than a conventional attachment.
Then the V part of the Mab can get to work but in addition whatever is attached to the Fc region can also get to work.
As Lindy says, this is potentially a combination therapy in its own right and with the higher than normal avidity
I also say if the collaborators are looking at the Glycans/Avidimab in 'ICD ADC CAR-T Bispecifics and In vivo and In vitro
TSCM expansion' Then they must be quite serious outfits
Ain't that the truth!.... Though to be fair here we are only going to have that opportunity on commercial deal/s and clinical success which at least on the commercial deal/s front we have not had so all the play for....
The deal potential on Glycan Mabs/AvidiMab ... is acctually rather massive when you look at the TaG summary and listen to Cliffs words at the LSX presentation.... 5 Mabs... over 6 potential cancer targets multiple a broad range of applicability... i.e can be used in CAR T,bispecifics (hot areas) plus AvidiMab has potential to improve any MaB (massive potential that if proves true) All the collaborators are according to Cliff looking at both the MaBs and Avidimab in those multiple possible apllications.... So the number of potential deals on them could be rather huge.... the first would be nice though and get that ball rolling :) ...
Actually, thinking about it, 33p was a good buying opportunity if you sold at 65p!
Crumbs, very true, if only we knew which way it’s going to go, we’d all be millionaires.